Loss of smell (hyposmia) due to a virus and the associated loss of taste affects more than 65 million people between the US, Europe and Japan and millions more worldwide, significantly impacting quality of life. Cyrano Therapeutics has developed an intranasal treatment to address this issue, with the first products focused on restoring olfactory function for those suffering from long-term post-viral hyposmia. The FLAVOR trial is testing an advanced nasal spray with a groundbreaking pharmaceutical formulation to help people recover their sense of smell and taste and enjoy life again.
Why This Flavor Trial Matters
Hyposmia can lead to difficulties in daily life, including safety concerns (like detecting gas leaks) and reduced enjoyment of food. Research has also linked smell loss to emotional and mental health challenges such as depression and anxiety. Cyrano Therapeutics is developing a therapy to restore this essential sense, which could greatly improve patients’ overall well-being. This trial is the next step in that development process.
Restoring 2 of the Main 5 Senses
Smell and taste represent two of the main five senses we have as human beings. While the restoration of these senses have been historically under-researched, the work being done at Cyrano Therapeutics is shifting the landscape. As we continue to lead the charge in this important area, our findings could provide hope for millions who have lost this essential sense.